
A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic/Wegovy and Zepbound, clinical trial results show. Ecnoglutide helped people lose between 9% to 13% of their body weight on average after 40 weeks of treatment, according to phase 3 trial findings published June 21 in The Lancet Diabetes &… read on > read on >